Effect of interferon-α on cognitive functioning in patients with chronic hepatitis C

Journal of the International Neuropsychological Society

Volumn 11, Issue 1, 2005, Pages 16-22

  Hilsabeck, Robin C ^a,b,c,d   Hassanein, Tarek I ^b   Ziegler, Elizabeth A ^b   Carlson, Meghan D ^b   Perry, William ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Psychology Service 116B   (United States)

Author keywords

Chronic liver disease; HCV; Neuropsychological impairment

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; BIOLOGICAL RESPONSE MODIFIER;

ADULT; ARTICLE; CHI SQUARE TEST; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FISHER EXACT TEST; HEPATITIS C; HUMAN; MALE; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS OF COVARIANCE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SYMBOLISM; TASK PERFORMANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL RESPONSE MODIFIERS; COGNITION DISORDERS; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

EID: 15044342254     PISSN: 13556177     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1355617705050022     Document Type: Article

References (56)

1. Adams, F., Fernandez, F., & Mavligit, G. (1988). Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. Journal of Neurooncology, 6, 355-359.
2. Adams, F., Quesada, J.R., & Gutterman, J.U. (1984). Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. Journal of the American Medical Association, 252 938-941.
3. Akwa, Y., Hassett, D.E., Eloranta, M.L., Sandberg, K., Masliah, E., Powell, H., Whitton, J.L., Bloom, F.E., & Campbell, I.L. (1998). Transgenic expression of IFN-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. Journal of Immunology, 161, 5016-5026.
4. Amato, R., Meyers, C.A., Ellerhorst, J., Finn, L., Kilbourn, R., Sella, A., & Logothetis, C. (1995). A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Annals of Oncology, 6, 911-914.
5. Basso, M.R., Bornstein, R.A., & Lang, J.M. (1999). Practice effects on commonly used measures of executive function across twelve months. Clinical Neuropsychologist, 13, 283-292.
6. Beck, A.T. & Steer, R.A. (1990). Beck Anxiety Inventory: Manual. San Antonio, TX: The Psychological Corporation.
7. Beck, A.T., Steer, R.A., & Brown, G.K. (1996). Beck Depression Inventory-Second Edition: Manual. San Antonio, TX: The Psychological Corporation.
8. Belza, B.L. (1995). Comparison of self-reported fatigue in rheumatoid arthritis and controls. Journal of Rheumatology, 22, 639-643.
9. Belza, B.L., Henke, C.J., Yelin, E.H., Epstein, W.V., & Gilliss, C.L. (1993). Correlates of fatigue in older adults with rheumatoid arthritis. Nursing Research, 42, 93-99.
10. Bonkovsky, H.L., Woolley, J.M., & The Consensus Interferon Study Group. (1999). Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264-270.
11. Calvert, M. & Gresser, I. (1979). Interferon enhances the excitability of cultured neurons. Nature, 278, 558-560.
12. Caraceni, A., Gangeri, L., Martini, C., Belli, F., Brunelli, C., Baldini, M., Mascheroni, L., Lenisa, L., & Cascinelli, N. (1998). Neurotoxicity of interferon-α in melanoma therapy. Cancer, 83, 482-489.
13. Crow, Y.J., Black, D.N., Ali, M., Bond, J., Jackson, A.P., Lefson, M., Michaud, J., Roberts, E., Stephenson, J.B., Woods, C.G., & Lebon, P. (2003). Cree encephalitis is allelic with Aicardi-Goutières syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. Journal of Medical Genetics, 40, 183-187.
14. Daniels, H.M, Meager, A., Eddleston, A.L.W.F., Alexander, G.J.M., & Williams, R. (1990). Spontaneous production of tumor necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection. Lancet, 335, 875-877.
15. Davis, G.L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S.C., Trepo, C., Shiffman, M.L., Zeuzem, S., Craxi, A., Ling, M.H., Albrecht, J. (1998). Interferon alfa-2b alone or in combination with ribavirn for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine, 339, 1493-1499.
16. de Boer, A.G., & Breimer, D.D. (1998). Cytokines and blood-brain barrier permeability. In H.S. Sharma & J. Westman (Eds.), Progress in brain research, volume 115 (pp. 425-451). New York: Elsevier Science.
17. Dikmen, S.S., Heaton, R.K., Grant, I., & Temkin, N.R. (1999). Test-retest reliability and practice effects of Expanded Halstead-Reitan Neuropsychological Test Battery. Journal of the International Neuropsychological Society, 5, 346-356.
18. Dwight, M.M., Kowdley, K.V., Russo, J.E., Ciechanowski, P.S., Larson, A.M., & Katon, W.J. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychsomatic Research, 49, 311-317.
19. Fontana, R.J. (2000). Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Digestive Diseases, 18, 107-116.
20. Forton, D.M., Taylor-Robinson, S.D., & Thomas, H.C. (2002a . Reduced quality of life in hepatitis C - is it all in the head? Journal of Hepatology, 36, 435-438.
21. Forton, D.M., Thomas, H.C., Murphy, C.A., Allsop, J.M., Foster, G.R., Main, J., Wesnes, K.A., & Taylor-Robinson, S.D. (2002b . Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 35, 433-439.
22. Foster, G.R., Goldin, R.D., & Thomas, H.C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209-212.
23. Gisslinger, H., Svoboda, T., Clodi, M., Gilly, B., Ludwig, H., Havelec, L., & Luger, A. (1993). Interferon-alpha stimulates the hypothalamic-pituitary adrenal axis in vivo and in vitro. Neuroendocrinology, 57, 489-495.
24. Heaton, R.K., Grant, I., & Matthews, C.G. (1991). Comprehensive norms for an expanded Halstead-Reitan battery: Demographic corrections, research findings, and clinical applications. Odessa, FL: Psychological Assessment Resources, Inc.
25. Hilsabeck, R.C., Hassanein, T.I., Carlson, M.D., Ziegler, E.A., & Perry, W. (2003). Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. Journal of the International Neuropsychological Society, 9, 847-854.
26. Hilsabeck, R.C., Perry, W., & Hassassein, T.I. (2002). Neuropsychological impairment in patients with chronic hepatitis C. Hepatology, 35, 440-446.
27. Juengling, F.D., Ebert, D., Gut, O., Engelbrecht, M.A., Rasenack, J., Nitzsche, E.U., Bauer, J., & Lieb, K. (2000). Prefrontal cortical hypmetabolism during low-dose interferon alpha treatment. Psychopharmacology, 152, 383-389.
28. Lezak, M.D. (1995). Neuropsychological Assessment (3rd ed.). New York: Oxford University Press.
29. Licinio, J., Kling, M.A., & Hauser, P. (1998). Cytokines and brain function: Relevance to interferon-α-induced mood and cognitive changes. Seminars in Oncology, 25, S30-S38.
30. Lineweaver, T.T. & Chelune, G.J. (2003). Use of the WAIS-III and WMS-III in the context of serial assessments: Interpreting reliable and meaningful change. In D.S. Tulsky, M.F. Ledbetter, G.J. Chelune, R.K. Heaton, R.A. Bornstein, R. Ivnik, & A. Prifitera (Eds.), Clinical Interpretation of the WAIS-III and WMS-III (pp. 303-337). New York: Academic Press.
31. Mapou, R.L., Law, W.A., Wagner, K., Malone, J.L., & Skillman, D.R. (1996). Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic immunodeficiency virus-1-infected individuals. Journal of Neuropsychiatry, 8, 74-81.
32. Mattson, K., Niiranen, A., Laaksonen, R., & Cantell, K. (1984). Psychometric monitoring of interferon neurotoxicity. Lancet, 1 275-276.
33. Mayr, N., Zeitlhofer, J., Deecke, L., Fritz, E., Ludwig, H., & Gisslinger, H. (1999). Neurological function during long-term therapy with recombinant interferon alpha. Journal of Neuropsychiatry and Clinical Neurosciences, 11, 343-348.
34. McHorney, C.A., Ware, J.E., Lu, J.F.R., & Sherbourne, C.D. (1994). The MOS 36-item Short-form Health Survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Medical Care, 32, 40-66.
35. McHorney, C.A., Ware, J.E., & Raczek, A.E. (1993). The MOS 36-item short-form health status survey (SF-36): II Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247-263.
36. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., & Albrecht J.K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339, 1485-1492.
37. Meyers, C.A. (1999). Mood and cognitive disorders in cancer patients receiving cytokine therapy. Advances in Experimental Medicine and Biology, 461, 75-81.
38. Meyers, C.A., Obbens, E.A.M.T., Scheibel, R.S., & Moser, R.P. (1991a). Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer, 68, 88-91.
39. Meyers, C.A., Scheibel, R.S., & Forman, A.D. (1991b). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology, 41, 672-676.
40. Niiranen, A., Laaksonen, R., Iivanainen, M., Mattson, K., Farkkila, M., & Cantell, K. (1988). Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatrica Scandinavica, 78, 622-626.
41. Panitch, H.S., Gomez-Plascencia, J., Norris, F.H., Cantell, H., & Smith, R.A. (1986). Subacute sclerosing panecephalitis: remission after treatment with intraventricular interferon. Neurology, 36, 562-566.
42. Pavol, M.A., Meyers, C.A., Rexer, J.L., Valentine, A.D., Mattis, P.J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon alpha therapy for leukemia. Neurology, 45 947-950.
43. Reitan, R.M. & Wolfson, D. (1993). The Halstead-Reitan Neuropsychological Test Battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press.
44. Renault, P.F., Hoofnagle, J.H., Park, Y., Mullen, K.D., Peters, M., Jones, D.B., Rustgi, V., & Jones, E.A. (1987). Psychiatric complications of long-term interferon alfa therapy. Archives of Internal Medicine, 147, 1577-1580.
45. Rohatiner, A.Z.S., Prior, P.F., Burton, A.C., Smith, A.T., Balkwill, F.R., & Lister, T.A. (1983). Central nervous systemic toxicity of interferon. British Journal of Cancer, 47, 419-422.
46. Shibata, M. & Blatteis, C.M. (1991). Human recombinant tumor necrosis factor and interferon affect the activity of neuron in the organum vasculosum laminea terminalis. Brain Research, 562, 323-326.
47. Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., & Oishi, R. (1997). Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Research, 747, 348-351.
48. Smedley, H., Katrak, M., Sikora, K., & Wheeler, T. (1983). Neurological effects of recombinant human interferon. British Medical Journal, 286, 262-264.
49. Smith, A. (1982). Symbol Digit Modalities Test (SDMT) manual (revised). Los Angeles, CA: Western Psychological Services.
50. Smith, R.A., Norris, F., Palmer, D., Bernhardt, L., & Wills, R.J. (1985). Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clinical Pharmacology and Therapeutics, 37, 85-88.
51. Suter, C.C., Westmoreland, B.F., Sharbrough, F.W., & Hermann Jr., R.C. (1984). Electroencephalographic abnormalities in interferon encephalopathy: A preliminary report. Mayo Clinic Proceedings, 59, 847-850.
52. Taylor, M.J. & Heaton, R.K. (2001). Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. Journal of the International Neuropsychological Society, 7, 867-874.
53. Valentine, A.D., Meyers, C.A., Kling, M.A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-α therapy. Seminars in Oncology, 25, S39-S47.
54. Ware, J.E. & Sherbourne, C.D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30, 473-483.
55. Yamada, T. & Yamnaka, I. (1995). Microglial localization of α-interferon receptor in human brain tissues. Neuroscience Letters, 189, 73-76.
56. Zachary, R.A. (1986). Shipley Institute of Living Scale Revised manual. Los Angeles, CA: Western Psychological Services.